Publications by authors named "Nicholas Latimer"

Claim this Profile
U
Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs.
Audrey Petitjean, Huiyu Shang, Ash Bullement, Nicholas Latimer

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmented two-stage estimation for treatment switching in oncology trials: Leveraging external data for improved precision.
Harlan Campbell, Nicholas Latimer, Jeroen P Jansen, Shannon Cope

Stat Methods Med Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Assessment of the Maturity of Cancer Survival Data Used in Economic Models for the National Institute for Health and Care Excellence's Single Technology Appraisals.
Jiyeon Kang, John Cairns, Nicholas R Latimer, Stephen Duffield, Richard Grieve

Value Health· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using inverse probability of censoring weighting to estimate hypothetical estimands in clinical trials: Should we implement stabilisation, and if so how?
Jingyi Xuan, Shahrul Mt-Isa, Nicholas R Latimer, Helen Bell Gorrod, William Malbecq

Stat Methods Med Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Immature Survival Data for Anticancer Drugs Presented to the National Institute for Health and Care Excellence Between 2018 and 2022.
Cara L Gibbons, Nicholas R Latimer

Value Health· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is inverse probability of censoring weighting a safer choice than per-protocol analysis in clinical trials?
Jingyi Xuan, Shahrul Mt-Isa, Nicholas Latimer, Helen Bell Gorrod, William Malbecq

Stat Methods Med Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusting for switches to multiple treatments: Should switches be handled separately or combined?
Helen Bell Gorrod, Shahrul Mt-Isa, Jingyi Xuan, Kristel Vandormael, William Malbecq, Nicholas Latimer

Stat Methods Med Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Simulation Study.
Abualbishr Alshreef, Nicholas Latimer, Paul Tappenden, Simon Dixon

Med Decis Making· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation-A Tutorial.
Ash Bullement, Mark Edmondson-Jones, Patricia Guyot, Nicky J Welton, Gianluca Baio, Nicholas R Latimer

Pharmacoeconomics· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?
Nicholas R Latimer, Kurt Taylor, Anthony J Hatswell, Sophia Ho, Gabriel Okorogheye

Pharmacoeconomics· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling.
Kurt Taylor, Nicholas R Latimer, Thomas Douglas, Anthony J Hatswell, Sophia Ho

Pharmacoeconomics· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know.
Nicholas R Latimer, Mark J Rutherford

Pharmacoeconomics· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach.
Ash Bullement, Mark Edmondson-Jones, Nicholas Latimer

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments.
Jen-Yu Amy Chang, James B Chilcott, Nicholas R Latimer

Pharmacoeconomics· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters.
Angus C Jennings, Mark J Rutherford, Nicholas R Latimer, Michael J Sweeting, Paul C Lambert

Value Health· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate and colorectal cancer in the UK.
Phillippa Lally, Fiona Kennedy, Susan Smith, Rebecca J Beeken, Caroline Buck, Nicholas Latimer

Cancer Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
Sangyu Lee, Paul C Lambert, Michael J Sweeting, Nicholas R Latimer, Mark J Rutherford

Value Health· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the multi-state natural history of rare diseases with heterogeneous individual patient data: A simulation study.
Jonathan Broomfield, Keith R Abrams, Suzanne Freeman, Nicholas Latimer, Mark J Rutherford

Stat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
Nicholas R Latimer, Alice Dewdney, Marco Campioni

BMC Med Res Methodol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Michael J Sweeting, Mark J Rutherford, Dan Jackson, Sangyu Lee, Nicholas R Latimer

Med Decis Making· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment.
Ash Bullement, Matthew D Stevenson, Gianluca Baio, Gemma E Shields, Nicholas R Latimer

Med Decis Making· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
Antonia Morga, Nicholas R Latimer, Martin Scott, Neil Hawkins, Michael Schlichting

Value Health· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Propensity Score and Instrumental Variable Techniques in Observational Transplantation Studies: An Overview and Worked Example Relating to Pre-Transplant Cardiac Screening.
Ailish Nimmo, Nicholas Latimer, Gabriel C Oniscu, Rommel Ravanan, Dominic M Taylor

Transpl Int· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness.
Nicholas R Latimer, Amanda I Adler

BMJ Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials.
Amanda I Adler, Nicholas R Latimer

JAMA· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis